Loading...
Lumos Pharma, Inc.
LUMO•NASDAQ
Healthcare
Biotechnology
$4.34
$0.00(0.00%)
Lumos Pharma, Inc. (LUMO) Stock Overview
Explore Lumos Pharma, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for LUMOStats details for LUMO are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations
Strong Buy
0
Buy
0
Hold
1
Sell
0
Strong Sell
0
Price Targets
Low$0.00
Average$0.00
High$0.00
Company Profile
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
CEO
Mr. Richard J. Hawkins
Employees
30
Headquarters
4200 Marathon Boulevard, Austin, TX
Founded
2011